Accessibility Statement

SASB Index


This report outlines how our existing disclosures align with the recommended metrics for the SASB Biotechnology & Pharmaceuticals standards. All data is for the year ended December 31, 2023, unless otherwise noted.


Safety of Clinical Trial Participants

SASB Code
Accounting Metric
Response
HC-BP-210a.1
Accounting Metric:
Discussion, by world region, of management process for ensuring quality and patient safety during clinical trials
Response:
HC-BP-210a.2
Accounting Metric:
Number of FDA Sponsor Inspections related to clinical trial management and pharmacovigilance that resulted in: (1) Voluntary Action Indicated (VAI) and (2) Official Action Indicated (OAI)
Response:
Not Disclosing
HC-BP-210a.3
Accounting Metric:
Total amount of monetary losses as a result of legal proceedings associated with clinical trials in developing countries
Response:
Not Disclosing

Access to Medicines

SASB Code
Accounting Metric
Response
HC-BP-240a.1
Accounting Metric:
Description of actions and initiatives to promote access to health care products for priority diseases and in priority countries as defined by the Access to Medicine Index
Response:
HC-BP-240a.2
Accounting Metric:
List of products on the WHO List of Prequalified Medicinal Products as part of its Prequalification of Medicines Programme (PQP)
Response:
Lilly does not have products on the PQP

Affordability & Pricing

SASB Code
Accounting Metric
Response
HC-BP-240b.1
Accounting Metric:
Number of settlements of Abbreviated New Drug Application (ANDA) litigation that involved payments and/or provisions to delay bringing an authorized generic product to market for a defined time period
Response:
Zero. Lilly does not pay for delays.
HC-BP-240b.2
Accounting Metric:
Percentage change in: (1) average list price and (2) average net price across U.S. product portfolio compared to previous year
Response:
HC-BP-240b.3
Accounting Metric:
Percentage change in: (1) list price and (2) net price of product with largest increase compared to previous year
Response:
Not Disclosing

Drug Safety

SASB Code
Accounting Metric
Response
HC-BP-250a.1
Accounting Metric:
List of products listed in the Food and Drug Administration’s (FDA) MedWatch Safety Alerts for Human Medical Products database
Response:
HC-BP-250a.2
Accounting Metric:
Number of fatalities associated with products as reported in the FDA Adverse Event Reporting System
Response:
HC-BP-250a.3
Accounting Metric:
Number of recalls issued, total units recalled
Response:
HC-BP-250a.4
Accounting Metric:
Total amount of product accepted for takeback, reuse, or disposal
Response:
Not Disclosing
HC-BP-250a.5
Accounting Metric:
Number of FDA enforcement actions taken in response to violations of current Good Manufacturing Practices (cGMP), by type
Response:
Not Disclosing

Conterfeit Drugs

SASB Code
Accounting Metric
Response
HC-BP-260a.1
Accounting Metric:
Description of methods and technologies used to maintain traceability of products throughout the supply chain and prevent counterfeiting
Response:
HC-BP-260a.2
Accounting Metric:
Discussion of process for alerting customers and business partners of potential or known risks associated with counterfeit products
Response:
HC-BP-260a.3
Accounting Metric:
Number of actions that led to raids, seizure, arrests, and/or filing of criminal charges related to counterfeit products
Response:
Not Disclosing

Ethical Marketing

SASB Code
Accounting Metric
Response
HC-BP-270a.1
Accounting Metric:
Total amount of monetary losses as a result of legal proceedings associated with false marketing claims
Response:
Not Disclosing
HC-BP-270a.2
Accounting Metric:
Description of code of ethics governing promotion of off-label use of products
Response:

Employee Recruitment, Development & Retention

SASB Code
Accounting Metric
Response
HC-BP-330a.1
Accounting Metric:
Discussion of talent recruitment and retention efforts for scientists and research and development personnel
Response:
HC-BP-330a.2
Accounting Metric:
(1) Voluntary and (2) involuntary turnover rate for: (a) executives/senior managers, (b) mid level managers, (c) professionals, and (d) all others
Response:

Supply Chain Management

SASB Code
Accounting Metric
Response
HC-BP-430a.1
Accounting Metric:
Percentage of (1) entity's facilities and (2) Tier I suppliers' facilities participating in the Rx-360 International Pharmaceutical Supply Chain Consortium audit program or equivalent third party audit programs for integrity of supply chain and ingredients
Response:

Business Ethics

SASB Code
Accounting Metric
Response
HC-BP-510a.1
Accounting Metric:
Total amount of monetary losses as a result of legal proceedings associated with corruption and bribery
Response:
Not Disclosing
HC-BP-510a.2
Accounting Metric:
Description of code of ethics governing interactions with healthcare professionals
Response:

Activity Metrics

SASB Code
Activity Metric
Response
HC-BP-000.A
Activity Metric:
Number of patients treated
Response:
HC-BP-000.B
Activity Metric:
Number of drugs (1) in portfolio and (2) in research and development (Phases 1-3)
Response:

See important information about our Sustainability report.